Neuropathology and neurochemistry of Parkinson's disease: The never-ending story or the story with no beginning?

Minerva Psichiatrica

Volumn 50, Issue 1, 2009, Pages 1-26

  Uversky, V N ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INSTITUTE FOR BIOLOGICAL INSTRUMENTATION   (Russian Federation)

Author keywords

Neuropsychology; Parkinson disease; Substantia nigra

Indexed keywords

ALPHA SYNUCLEIN; IRON; NEUROTOXIN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE;

AUTONOMIC DYSFUNCTION; AUTOPHAGY; DEMENTIA; DEPRESSION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; GENETIC PREDISPOSITION; GLIA CELL; NEUROCHEMISTRY; NEUROPATHOLOGY; OXIDATIVE STRESS; PARKINSON DISEASE; REVIEW; SLEEP DISORDER; SMELLING DISORDER; VISUAL HALLUCINATION;

EID: 67249152339     PISSN: 03911772     EISSN: 18271731     Source Type: Journal    
DOI: None     Document Type: Review

References (252)

1. Olanow CW, Tatton WG. Etiology and pathogenesis of Parkinson's disease. Annu Rev Neurosci 1999;22:123-44.
2. Moghal S, Rajput AH, D'Arcy C, Rajput R. Prevalence of movement disorders in elderly community residents. Neuroepidemiology 1994; 13:175-8.
3. Fahn S. Description of Parkinson's disease as a clinical syndrome. Ann NY Acad Sci 2003;991:1-14.
4. Tanner CM. Is the cause of Parkinson's disease environmental or hereditary? Evidence from twin studies. Adv Neurol 2003;91:133-42.
5. Farrer MJ. Genetics of Parkinson disease: paradigm shifts and future prospects. Nat Rev Genet 2006;7:306-18.
6. Mizuno Y, Hattori N, Kitada T, Matsumine H, Mori H, Shimura H, et al. Familial Parkinson's disease. Alphasynuclein and parkin. Adv Neurol 2001;86:13-21.
7. Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, Bloch DA et al. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. AmJ Epidemiol 2003;157:1015-22.
8. Mitra K, Gangopadhaya PK, Das SK. Parkinsonism plus syndrome a review. Neurol India 2003;51:183-8.
9. Jankovic J. Parkinsonism-plus syndromes. Mov Disord 1989;4(Suppl 1):S95-119.
10. Hu MT, Bland J, Clough C, Ellis CM, Chaudhuri KR. Limb contractures in levodopa-responsive parkinsonism: a clinical and investigational study of seven new cases. J Neurol 1999;246:671-6.
11. Forno LS. Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 1996;55:259-72.
12. Lewy FH. Paralysis Agitans. Pathologische anatomic. In: M. Lewandowski, editor. Handbuch den Neurologie. Berlin: Springer Verlag: 1912. p. 920-33.
13. Parkinson J. An essay on shaking palsy. London; Sherwood, Neely and Jones; 1817.
14. Gounie-Devi M, Ramu MG, Venkatararn BS. Treatment of Parkinson's disease in "Ayurveda" ancient Indian system of medicine): discussion paper. J R Soc Med 1991;84:491-2.
15. Duvoisin RC. A brief history of parkinsonism. Neurol Clin 1992;10:301-16.
16. Jellinger KA. Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution a pilot study. Acta Neuropathol 2003;106:191-201.
17. den Hartog Jager WA, Bethlem J. The distribution of Lewy bodies in the central and autonomic nervous systems in idiopathic paralysis agitans. J Neurol Neurosurg Psychiatry 1960;23:283-90.
18. Kosaka K. Lewy bodies in cerebral cortex, report of three cases. Acta Neuropathol (Berl) 1978;42:127-34.
19. Kosaka K, Mehraein P. Dementia-Parkinsonism syndrome with numerous Lewy bodies and senile plaques in cerebral cortex. Arch Psychiatr Nervenkr 1979;226:241-50.
20. Goedert M. Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci 2001;2:-192-501.
21. Hague K, Lento P, Morgello S, Caro S. Kaufmann H. The distribution of Lewy bodies in pure autonomic failure: autopsy findings and review of the literature. Acta Neuropathol (Berl) 1997;94:192-6.
22. Jackson M, Lennox G, Balsitis M, Lowe J. Lewy body dysphagia. J Neurol Neurosurg Psychiatry 1995:58:756-58.
23. Hansen LA, Galasko D. Lewy body disease. Curr Opin Neurol Neurosurg 1992:5:889-94.
24. Perry RH, Irving D, Tomlinson BE. Lewy body prevalence in the aging brain: relationship to neuropsychiatric disorders, Alzheimer-type pathology and catecholaminergic nuclei. J Neurol Sci 1990;100:223-33.
25. McKeith IG, Mosimann UP. Dementia with Lewy bodies and Parkinson's disease. Parkinsonism Relat Disord 2004;10(Suppl 1):S15-8.
26. Tsuboi Y, Uchikado H, Dickson DW. Neuropathology of Parkinson's disease dementia and dementia with Lewy bodies with reference to striatal pathology. Parkinsonism Relat Disord 2007;13(Suppl 3):S221-4.
27. Galpern WR, Lang AE. Interface between tauopathies and synucleinopathies: a tale of two proteins. Ann Neurol 2006;59:449-58.
28. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ. Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997;388:839-40.
29. McKeith IG, Galasko D, Kosaka K, Perry EK. Dickson DW, Hansen LA et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47: 1113-24.
30. McKeith I, Mintzer J, Aarsland D, Burn D, Chiu H, Cohen-Mansfield J et al. Dementia with Lewy bodies. Lancet Neurol 2004;3:19-28.
31. Emre M. Dementia in Parkinsons disease: cause and treatment. Curr Opin Neurol 2004;17:399-404.
32. Jellinger KA, Attems J. Does stniatal pathology distinguish Parkinson disease with dementia and dementia with Lewy bodies? Acta Neuropathol 2006;112:253-60.
33. Kosaka K, Yoshimura M, Ikeda K, Budka H. Diffuse type of Lewy body disease: progressive dementia with abundant cortical Lewy bodies and senile changes of varying degree a new disease? Clin Neuropathol 1984;3:185-92.
34. Deramecourt V, Bombois S, Maurage CA, Ghestem A. Drobecq H, Vanmechelen E et al. Biochemical staging of synucleinopathy and amyloid deposition in dementia with Lewy bodies. J Neuropathol Exp Neurol 2006;65:278-88.
35. Hansen L, Salmon D, Galasko D, Masliah E, Katzman R, DeTeresa R et al. The Iewy body variant of Alzheimer's disease: a clinical and pathologic entity. Neurology 1990;40:1-8.
36. Hansen LA, Masliah E, Galasko D, Terry RD. Plaque-only Alzheimer disease is usually the lewy body variant, and vice versa. J Neuropathol Exp Neurol 1993;52:648-54.
37. Kosaka K Dementia and neuropathology in lewy body disease. Adv Neurol 1993;60:456-63.
38. Gibb WR, Esiri MM, Lees AJ. Clinical and pathological features of diffuse cortical Lewy body disease (Lewy body dementia). Brain 1987;ll0:1131-53.
39. Perry RH, Irving D, Blessed G, Faiibatrn A, Perry EK. Senile dementia of Lewy body type A clinically and netimpathologically distinct form of Lewy body deinenna in the elderly. J Neurol Sci 1990;95: 119-39.
40. Byrne Fj, LoweJ, Godwin-Austen RB, Arie T, Jones R. Dementia and Parkinson's disease associated with diffuse cortical Lewy bodies. Lancet 1987;l:501.
41. Mayeux Il, DenaroJ, Hemenegildo N, Marder K, Tang MX, Cole U et al. A population-based investigation of Parkinson's disease with and without dementia. Relationship to age and gender. Arch Neurol 1992;49:492-7.
42. Aaisland D, And.ersen K, LarsenJP, Lolk A, Nielsen H, Kragh-Sorensen P. Risk of dementia in Parkinson's disease a community-based, prospective study. Neurology 2001;56:730-6.
43. McKeith EG, Dickson DW, Lowe J, Ernre M, O'Brien JT, Feldman H et al. Diagnosis and management of dementia with Iewy bodies: third report of the DLB Consortium. Neurology 2005;65: 1863-72.
44. Duda JE. Pathology and neurotransmitter abnormalities of dementia with Lewy bodies. Dement Geriatr Cogn Disord 2004;17(Suppl 1):3-14.
45. Lalli S, Albanese A Rivastigmine in Parkinson's disease dementia. Expert Rev Neurother 2008;8:1181-8.
46. Schenck CH, Bundlie SR. Mahowald MW. Delayed erneigence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology 1996;46:388-93.
47. Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 199952:1908-1910.
48. Anuilf I, Leu S, Oudiette D. Abnormal sleep and sleepiness in Parkinson's disease. Curr Opin Neurol 2008;21:472-7.
49. De Cock VC, Vidailhet M, Arnulf I. Sleep disturbances in patients with parkinsonism. Nat clin Pract Neurol 2008;4:254-66.
50. Del Tredici K, Rub U, De Vos RA, Bohl JR. Braak H. Where does parkinson disease pathology begin in the brain? J Neuropathol Exp Neurol 2002;61:413-26.
51. Arnuif I. Excessive daytime sleepiness in parkinsonism Sleep Med Rev 2005;9:185-200.
52. Fronczek K, Overeem S, Lee SY, Hegeman IM, van Pelt J, van J. Duinen SG et al. Hypocretin (orexin) loss in Parkinson's disease. Brain 2007; 130:1577-85.
53. Thannickal TC, Lai YY, Siegel JM. Hypocretin (orexin) cell loss In Parkinson's disease. Brain 2007;130:1586-95.
54. Tanner CM, Vogel C, Goetz CG, Klawans HL. Hallucinations in Parkinson's disease: a population study. Ann Neurol 1983;14:136.
55. Goetz CG, Stebbins GT. Mortality and hallucinations in nursing home patients with advanced Parkinson's disease. Neurology 1995;45:669-71.
56. Nomura T, Inoue Y, Mitani H, Kawahara R, Miyake M, Nakashima K. Visual hallucinations as REM sleep behavior disorders in patients with Parkinson's disease. Mov Disord 2003;18:812-7.
57. Kalaitzakis ME, Christian LM, Moran LB, Graeber MB, Pearce RK, Gentleman SM. Dementia and visual hallucinations associate with limbic pathology in Parkinson's disease. Parkinsonism Relat Disord 2008 (Epub ahead of print].
58. Cummings JL. Depression and Parkinson's disease: a review. Am J Psychiatry 1992;149:443-54.
59. Brooks DJ, Doder M. Depression in Parkinson's disease. Curr Opin Neurol 2001;14:465-70.
60. Mayeux R, Stem Y, Rosen J, Leventhal J. Depression, intellectual impairment, and Parkinson disease. Neurology 1981;31:645-50.
61. Lieberman A. Depression in Parkinson's disease a review. Acta Neurol Scand 2006;113:1-8.
62. Frisina PG, Borod JC, Foldi NS, Tenenbaum HR. Depression in Parkinson's disease: Health risks, etiology, and treatment options. Neuropsychiatr Dis Treat 2008;4:81-91.
63. Frisina PG, Haroutunian V, Libow LS. The neuropathological basis for depression in Parkinson's disease. Parkinsonism Relat Disord 2008 [Epub ahead of print].
64. Doty RL, Deems EM, Stellar S. Olfactory dysfunction in parkinsonism: a general deficit unrelated to neurologic signs, disease stage, or disease duration. Neurology 1988;38:1237-44.
65. Markopoulou K, Larsen KW Wszolek EK, Denson MA, Lang AE, Pfeiffer RF et al. Olfactory dysfunction in familial parkinsonism. Neurology 1997;49:1262-7.
66. Doty RL Olfaction in Parkinson's disease. Parkinsonism Relat Disord 2007;13(Suppl 3):S225-8.
67. Beach TG, White CL 3rd, Hiadik CL, Sabbagh MN, Connor DJ, Shill HA et al. Olfactory bulb alpha-synucleinopathy has high specificity and sensitivity for Lewy body disorders. Acts Neuropathol 2008 [Epub ahead of print].
68. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neuiobiol Aging 2003;24:197-211.
69. Waseem 5, Gwinn-Hardy K Path in Parkinson's disease. Common yet seldom recognized symptom is treatable. Postgrad Med 2001;110:33-4, 39-40, 46.
70. Snider SR. Fahn S, Isgreen WP, Cote U. Primary sensory symptoms in parkinsonism. Neurology 1976;26:423-9.
71. Scherder E, Wolters E, Polman C, Sergeant J, Swaab D. Pain in Parkinson's disease and multiple sclerosis: its relation to the medial and lateral pain systems. Neurosci Biobehav Rev 2005;29:1047-56.
72. Quinn NP, Koller WC, Lang AE, Marsden CD. Painful Parkinson's disease. Lancet 1986;1:1366-9.
73. Goetz CG, Tanner CM, Levy M, Wilson RS, Garron DC. Path in Parkinson's disease. Mov Disord 1986;1:45-9.
74. Ford B. Pain in Parkinson's disease. Clin Neurosci 1998;5:63-72.
75. Guieu R, PougetJ, Serratrice G. [Nociceptive threshold and Parkinson disease]. Rev Neurol (Paris) 1992;148:641-4.
76. Nolano M, Provitera V, Estraneo A, Selim MM, Capomaso G, Stancanelli A et al. Sensory deficit in Parkinson's disease: evidence of a cutaneous denervation. Brain 2008;131:1903-11.
77. Ikemura M, Saito Y, Sengoku R, Sakiyama Y, Hatsuta H, Kanemaru K et al. Lewy body pathology involves cutaneous nerves. J Neuiopathol Exp Neurol 2008;67:945-53.
78. Edwards LL, Quigley EM, Harned RK, Hofman R, Pfeiffer RE Characterization of swallowing and defecation in Parkinson's disease. Am J Gastroenterol 1994;89:15-25.
79. Hardoff R, Sula M, Tamir A, Soil A, Front A, Badarna S et al. Gastric emptying time and gastric motility in patients with Parkinson's disease. Mov Disord 2001;16:1041-7.
80. Verbaan D, Marinus J, Visser M, van Rooden SM, Stiggelbout AM, van Hilten JJ. Patient-reported autonomic symptoms in Parkinson disease. Neurology 2007;69:333-41.
81. Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurol 2003;2:107-6.
82. Natale G, Pasquali L, Ruggieri S, Paparelli A, Fornai F. Parkinson's disease and the gut: a well known clinical association in need of an effective cure and explanation. Neurogastroenterol Motil 2008;20:741-9.
83. Fornai F, Ruffoli R, Soldani P, Ruggieri S, Paparelli A. The "Parkinsonian heart": from novel vistas to advanced therapeutic approaches in Parkinson's disease. Cun Med Chem 2007;14:2421-8.
84. Probst A, Bloch A, Tolnay M. New insights into the pathology of Parkinson's disease: does the peripheral autonomic system become central? Eur J Neurol 2008;15(Suppl 1):1-4.
85. Singer C. Urinary dysfunction in Parkinson's disease. Clin Neurosci 1998;5:78-86.
86. Winge K, Fowler CJ. Bladder dysfunction in Parkinsonism: mechanisms, prevalence, symptoms, and management. Mov Disord 2006;21:737-45.
87. Fowler CJ. Update on the neurology of Parkinson's disease. Neurourol Urodyn 2007;26:103-9.
88. Nagatsu T, Sawada M. Cellular and molecular mechanisms of Parkinson's disease: neurotoxins, causative genes, and inflammatory cytokines. Cell Mol Neurobiol 2006;26:781-802.
89. Tansey MG, McCoy MK, Frank-Cannon TC. Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp Neurol 2007;208:1-25.
90. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997;276:20457.
91. Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, Ampuero I et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 2004;55:164-73.
92. Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S et al. Ala3OPro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 1998;18:106-8.
93. Singleton A, Gwinn-Hardy K, Sharabi Y, Li ST, Holmes C, Dendi R et al. Association between cardiac denervation and parkinsonism caused by alpha-synuclein gene triplication. Brain 2004;127:768-72.
94. Singleton AB, Farrer M, Johnson J, Singleton A, Hague 5, Kachergus J et al. alpha-Synuclein locus triplication causes Parkinson's disease. Science 2003;302:841.
95. Farrer M, Kachergus J, Fomo L, Lincoln 5, Wang DS, Hulihan M et al. Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann Neurol 2004;55:174-9.
96. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc Natl Acad Sci U S A 1998;95:6469-73.
97. Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A et al. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 2000;287:1265-9.
98. Feany MB, Bender WW. A Drosophila model of Parkinson's disease. Nature 2000;404:394-8.
99. Trojanowski JQ, Lee VM. Parkinson's disease and related alpha-synucleinopathies are brain amyloidoses. Ann N Y Acad Sci 2003;991:107-10.
100. Dickson DW. Alpha-synuclein and the Iewy body disorders. Curr Opin Neurol 2001;14:423-32.
101. Goedert M. Parkinson's disease and other alpha-synucleinopathies. Clin Chem Lab Med 2001;39:308-12.
102. Dev KK, Hofele K, Barbieri S, Buchman VL, van der Putten H. Part II: alpha-synuclein and its molecular pathophysiological role in neurodegenerative disease. Neuropharmacology 2003;45:14-44.
103. Uversky VN, Fink AL, Biophysical properties of human alpha-synuclein and its role in Parkinson's disease. In: Pandalai SG, editor. Recent research developments in proteins. Kerala, India: Transworld Research Network; 2002. p. 153-86.
104. Uversky VN. Aipha-synuclein misfolding and neurodegenerative diseases. Curr Protein Pept Sci 2008;9:507-40.
105. Uversky VN. Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation. J Neurochem 2007;103:17-37.
106. Gomez-Tortosa E, Newell K, Irizarry MC, Sanders JL, Hyman BT. alpha-Synuclein immunoreactivity in dementia with Lewy bodies: morphological staging and comparison with ubiquitin immunostaining. Acts Neuropathol (Berl) 2000;99:352-7.
107. Lowe J, Blanchard A, Morrell K, Lennox G, Reynolds L, Billett M et al. Ubiquitin is a common factor in intermediate filament inclusion bodies of diverse type in man, including those of Parkinson's disease, Pick's disease, and Alzheimer's disease, as well as Rosenthal fibres in cerebellar astrocytomas, cytoplasmic bodies in muscle, and mallory bodies in alcoholic liver disease. J Pathol 1988;155:9-15.
108. Kuusisto E, Parkkinen L, Alafuzoff I. Morphogenesis of Lewy bodies: dissimilar incorporation of alphasynuclein, ubiquitin, and p62. J Neuropathol Exp Neurol 2003;62:1241-53.
109. Shults CW. Lewy bodies. Proc Nati Acad Sd U S A 2006;103:1661-8.
110. Wolman L, Roy S. The substantia nigra in Parkinsonisrn. J Chin Pathol 1969;22:507-8.
111. Roy 5, Wolman L. Ultrastructural observations in Parkinsonism. J Pathol 1969;99:39-44.
112. Arima K, Ueda K, Sunohara N, Hirai 5, Izumiyama Y. Tonozuka-Uehara H et al. Immunoelectron-microscopic demonstration of NACP/alpha-synuclein- epitopes on the filamentous component of Lewy bodies in Parkinson's disease and in dementia with Lewy bodies. Brain Res 1998;808:93-100.
113. Braak H, Sandmann-Keil D, Gal W, Braak E. Extensive axonal Lewy neurites in Parkinson's disease: a novel pathological feature revealed by alpha-synuclein immunocytochemistry. Neurosci Len 1999;265:67-9.
114. Braak H, Braak E, Yilmazer D, de Vos RA, Jansen EN, Bohi J et al. Amygdala pathology in Parkinson's disease. Acta Neuropathol (Berl) 1994;88:493-500.
115. Dickson DW, Roan D, Crystal H, Mark MH, Davies P, Kress Y et al. Hippocampal degeneration differentiates diffuse Lewy body disease (DLBD) from Alzheimer's disease: light and electron microscopic immunocytochemistry of CA2-3 neurites specific to DLBD. Neurology 1991 ;41:1402-9.
116. Iwai A, Masliah E, Yoshimoto M, Ge N, Flanagan L, de Silva HA et al. The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 1995;14:467-75.
117. Hashimoto M, Yoshimoto M, Sisk A, Hsu U, Sundsmo M, Kittel A et al. NACP, a synaptic protein involved in Alzheimer's disease, is differentially regulated during megakaryocyte differentiation. Biochem Biophys Res Commun 1997;237:611-6.
118. Abeliovich A, Schmitz Y, Farinas I, Choi-Lundberg D, Ho WH, Castillo PE et al. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 2000;25:239-52.
119. Li JY, Henning Jensen P, Dahistrom A. Differential localization of alpha-, beta- and gamma-synucleins in the rat CNS. Neuroscience 2002;113:463-78.
120. Tamo W, Imaizumi T, Tanji K, Yoshida H, Mon F, Yoshimoto M et al. Expression of alpha-synuclein, the precursor of non-amyloid beta component of Alzheimer's disease amyloid, in human cerebral blood vessels. Neurosci Lett 2002;326:5-8.
121. Chandra S Gallardo G, Fernandez-Chacon R, Schiuter OM, Sudhof TC. Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell 2005;123:383-96.
122. Jin J, Li GJ, Davis J, Zhu D, Wang Y, Pan C et al. Identification of novel proteins interacting with both alpha-synuclein and DJ-1. Mol Cell Proteomics 2007;6:845-59.
123. Schnack C, Danzer KM, Hengerer B, Gillardon F. Protein array analysis of oligomerization-induced changes in alpha-synuclein protein-protein interactions points to an interference with Cdc42 effector proteins. Neuroscience 2008;154:1450-7.
124. Thomas B, Beal MF. Parkinson's disease. Hum Mol Genet 2007;16 Spec No. 2:R183-94.
125. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998;392:605-8.
126. Valente EM, Salvi S, lalongo T, Marongiu R, Elia AE, Caputo V et al. PINK1 mutations are associated with sporadic early-onset parkinsonism. Ann Neurol 2004;56:336-41.
127. Valente EM, Abou-Sleiman PM, Caputo V, Muqit MM, Harvey K, Gispert S et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 2004;304: 1158-60.
128. Bonifati V Rizzu P, van Baren MJ, Schaap O, Breedveld GJ, Krieger E et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003;299:256-59.
129. Ramirez A. Heimbach A, Grundemann J, Stiller B, Hampshire D, Cid LP et al. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet 2006;38:1184-91.
130. Paisan-Ruiz C, Jam S, Evans EW, Gilks WP, Simon J, van der Brug M et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004;44:595-600.
131. Zimprich A, Muller-Myhsok B, Farrer M, Leitner P Sharma M, Hulihan M et al. The PARK8 locus in autosomal dominant parkinsonism: confirmation of linkage and further delineation of the disease-containing interval. Am J Hum Genet 2004;74: 11-9.
132. Golbe LI. The genetics of Parkinson's disease: a reconsideration. Neurology 1990:40:7-14.
133. Wood NW. Genetic risk factors in Parkinson's disease. Ann Neurol 1998;44:S58-62.
134. Hamilton BA. alpha-Synuclein A53T substitution associated with Parkinson disease also marks the divergence of Old World and New World primates. Genomics 2004;83:739-42.
135. Cookson MR. The biochemistry of Parkinson's disease. Annu Rev Biochem 2005;74:29-52.
136. Cookson MR, Hardy J, Lewis PA. Genetic neuropathology of Parkinson's disease. Int J Clin Exp Pathol 2008;1:217-31.
137. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S et al. Mutations in LRRK2 cause autosomaldominant parkinsonism with pleomorphic pathology. Neuron 2004;44:601-7.
138. Funayama M, Hasegawa K, Ohta E, Kawashima N, Komiyama M, Kowa H et al. An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family. Ann Neurol 2005;57:918-21.
139. Cookson MR, Xiromenisiou G, Singleton A. How genetics research in Parkinson's disease is enhancing understanding of the common idiopathic forms of the disease. Curr Opin Neurol 2005;18:706-11.
140. Lesage S, Ibanez P, Lohmann E, Pollak P, Tison F, Tazir M et al. G2019S LRRK2 mutation in French and North African families with Parkinson's disease. Ann Neurol 2005;58:784-7.
141. Kay DM, Kramer P, Higgins D, Zabetian CP, Payami H. Escaping Parkinson's disease: a neurologically healthy octogenarian with the LRRK2 G2019S mutation. Mov Disord 2005;20:1077-8.
142. Golub Y, Berg D, Calne DB, Pfeiffer RF, Uitti RJ, Stoessl AJ et al. Genetic factors influencing age at onset in LRRK2-linked Parkinson disease. Parkinsonism Relat Disord 2008 [Epub ahead of print].
143. Sulzer D. Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease. Trends Neurosci 2007;30:244-50.
144. Bedford L, Hay D, Paine S, Rezvani N, Mee M, Lowe J et al. Is malfunction of the ubiquitin proteasome system the primary cause of alpha-synuclemnopathies and other chronic human neurodegenerative disease? Biochim Biophys Acta 2008;1782:683-90.
145. McNaught KS, Shashidharan P, Perl DP, Jenner P, Olanow CW. Aggresome-related biogenesis of Lewy bodies. Eur J Neurosci 2002;16:2136-48.
146. Luo GR, Chen 5, Le WD. Are heat shock proteins therapeutic target for Parkinson's disease? int J Biol Sci 2007;3:20-6.
147. Auluck PK, Chan HY, Trojanowski JQ, Lee VM, Bonini NM. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science 2002;295:865-8.
148. Gao X, Hu H. Quality control of the proteins associated with neurodegenerative diseases. Acta Biochim Biophys Sin (Shanghai) 2008;40:612-8.
149. Winklhofer KF, Tatzelt J. The role of chaperones in Parkinson's disease and prion diseases. Handb Exp Pharmacol 2006:221-58.
150. Eskelinen EL. New insights into the mechanisms of macroautophagy in mammalian cells. Int Rev Cell Mol Biol 2008;266:207-47.
151. Kundu M, Thompson CB. Autophagy: basic principles and relevance to disease. Annu Rev Pathol 2008;3:427-55.
152. Eskelinen EL, Saftig P. Autophagy: A lysosomal degradation pathway with a central role in health and disease. Biochim Biophys Acta 2008 [Epub ahead of print].
153. Kroemer G, Levine B. Autophagic cell death: the story of a misnomer. Nat Rev Mol Cell Biol 2008:9:1004-10.
154. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008;132:27-42.
155. Shacka JJ, Roth KA, Zhang J. The autophagy-lysosomal degradation pathway: role in neurodegenerative disease and therapy. Front Biosci 2008;13:718-36.
156. Hara T, Nakamura K, Matsui M, Yamamoto A, Nakahara Y, Suzuki-Migishima R et al. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature 2006;441:885-9.
157. Komatsu M, Waguri S, Chiba T, Murata S Iwata J, Tanida I et al. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature 2006;441:880-4.
158. Wong ES, Tan JM, Soong WE, Hussein K, Nukina N, Dawson VL et al. Autophagy-mediated clearance of aggresomes is not a universal phenomenon. Hum Mol Genet 2008; 17:2570-82.
159. Cherra SJ, Chu CT. Autophagy in neuroprotection and neurodegeneration: A question of balance. Future Neurol 2008;3:309-23.
160. Martin U. Mitochondriopathy in Parkinson disease and amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 2006;65:1103-10.
161. Beal MF. Mitochondria take center stage in aging and neurodegeneration. Ann Neurol 2005;58:495-505.
162. Fiskum G, Starkov A, Polster BM, Chinopoulos C. Mitochondrial mechanisms of neural cell death and neuroprotective interventions in Parkinson's disease. Ann NY Acad Sci 2003;991:111-9.
163. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 2000;3:1301-6.
164. Sherer TB, Betarbet R, Testa CM, Seo BB, Richardson JR, Kim JH et al. Mechanism of toxicity in rotenone models of Parkinson's disease. J Neurosci 2003;23:10756-64.
165. Thyagarajan D, Bressman S, Bruno C, Przedborski S, Shanske 5, Lynch T et al. A novel mitochondrial 12SrRNA point mutation in parkinsonism, deafness, and neuropathy. Ann Neurol 2000;48:730-6.
166. Song DD, Shults CW, Sisk A, Rockenstein E, Masliah E. Enhanced substantia nigra mitochondrial pathology in human alpha-synuclein transgenic mice after treatment with MPTP. Exp Neurol 2004;186:158-72.
167. Hsu LJ, Sagara Y, Anoyo A, Rockenstein E, Sisk A, Mallory M et al. alpha-synuclein promotes mitochondrial deficit and oxidative stress. Am J Pathol 2000;157:401-10.
168. Fornai F, Schluter OM, Lenzi P Gesi M, Ruffoli R, Ferrucci M et al. Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein. Proc NatI Acad Sci U S A 2005;102:3413-8.
169. Koutsilieri E, Scheller C, Grunblatt E, Nara K, Li J, Riederer P. Free radicals in Parkinson's disease. J Neurol 2002;249(Suppl 2):II1-5.
170. German DC, Manaye K, Smith WK, Woodward DJ, Saper CB. Midbrain dopaminergic cell loss in Parkinson's disease: computer visualization. Ann Neurol 1989;26:507-14.
171. Hirsch E, Graybiel AM, Agid YA. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 1988;334:345-8.
172. Miyazaki I, Asanuma M. Dopaminergic neuron-specific oxidative stress caused by dopamine itself. Acta Med Okayama 2008;62:141-50.
173. Danielson SR, Andersen JK. Oxidative and nitrative protein modifications in Parkinson's disease. Free Radic Biol Med 2008;44:1787-94.
174. Chinta SJ, Andersen JK. Redox imbalance in Parkinson's disease. Biochim Biophys Acta 2008;1780:1362-7.
175. Ahlskog JE. Beating a dead horse: dopamine and Parkinson disease. Neurology 2007;69:1701-11.
176. Zhu BY. CNS dopamine oxidation and catechol-Omethyltransferase: importance in the etiology, pharmacotherapy, and dietary prevention of Parkinson's disease. IntJ Mol Med 2004;13:343-53.
177. Asanuma M, Miyazaki I, Ogawa N. Dopamine- or LDOPA-induced neurotoxicity: the role of dopaniine quinone formation and tyrosinase in a model of Parkinson's disease. Neurotox Res 2003;5:165-76.
178. Jenner P. Oxidative stress in Parkinson's disease. Ann Neurol 2003;53(Suppl 3):S26-36; discussion S36-28.
179. Sidhu A, Wersinger C, Vernier P. alpha-Synuclein regulation of the dopaminergic transporter: a possible role in the pathogenesis of Parkinson's disease. FEBS Lett 2004;565:1-5.
180. Halliday GM, Ophof A, Broe M, Jensen PH, Kettle E, Fedorow H et al. Alpha-synuclein redisthbutes to neuromelanin lipid in the substantia nigra early in Parkinson's disease. Brain 2005;128:2654-64.
181. Crichton RRDD, Ward J. Metal based neurodegenerative diseases: from molecular mechanisms to therapeutic strategies. Coordination Chem Rev 2008:252:1189-99.
182. Barnham KJ, Bush Al. Metals in Alzheimer's and Parkinson's diseases. Curr Opin Chem Biol 2008;12:222-8.
183. Stankiewicz JM, Brass SD. Role of iron in neurotoxicity: a cause for concern in the elderly? Curr Opin Clin Nutr Metab Care 2009;12:22-9.
184. Martin WR, Wider M, Gee M. Midbrain iron content in early Parkinson disease: a potential biomarker of disease status. Neurology 2008;70: 1411-7.
185. Crichton RR, Wilmet 5, Legssyer R, Ward RJ. Molecular and cellular mechanisms of iron homeostasis and toxicity in mammalian cells. J Inorg Biochem 2002;91 :9-18.
186. Gerlach M, Double KU, Youdim MB, Riederer P. Potential sources of increased iron in the substantia nigra of parkinsonian patients. J Neural Transm Suppl 2006:133-42.
187. Double KL, Gerlach M, Youdim MB, Riederer P. Impaired iron homeostasis in Parkinson's disease, J Neural Transm Suppl 2000:37-58.
188. Gerlach M, Double KL, Ben-Shachar D, Zecca U, Youdim MB, Riederer P. Neuromelanin and its interaction with iron as a potential risk factor for dopaminergic neurodegeneration underlying Parkinson's disease. Neurotox Res 2003:5:35-44.
189. Del Rio Hortega P. El tercer elemento de los centros nerviosos. Poder fagocitario y movilidad de Ia microglia. . Bol Soc Esp Biol Ano 1919;ix:154-66.
190. McGeer PL, McGeer EG. Glial reactions in Parkinsons disease. Mov Disord 2008;23:474-83.
191. Nimmerjahn A, Kirchhoff F, Helrnchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 2005;308:1314-8.
192. Graeber MB, Bise K, Mehraein P. CR3/43, a marker for activated human microglia: application to diagnostic neuropathology. Neuropathol Appi Neurobiol 1994;20:406-8.
193. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimers disease brains. Neurology 1988;38:1285-91.
194. McGeer Pl, Itagaki S, McGeer EG. Expression of the histocompatibility glycoprotein HLA-DR in neurological disease. Acta Neuropathol 1988;76:550-7.
195. Croisier E, Graeber MB. Glial degeneration and reactive gliosis in alpha-synucleinopathies: the emerging concept of primary gliodegeneration. Acta Neuropathol 2006;112:517-30.
196. Croisier E, Moran LB, Dexter DT, Pearce RK, Graeher MB. Microglial inflammation in the parkinsonian substantia nigra: relationship to alpha-synuclein deposition. J Neuroinflammation 2005;2:14.
197. Togo T, Iseki E, Marui W, Akiyama H, Ueda K, Kosaka K. Glial involvement in the degeneration process of Lewy body-hearing neurons and the degradation process of Lewy bodies in brains of dementia with Lewy bodies. J Neurul Sci 2001;184:71-5.
198. van Rossum D, Hanisch UK. Microglia. Metab Brain Dis 2004;19:393-411.
199. Wersinger C, Sidhu A. An inflammatory pathomechanism for Parkinson's disease? Curr Med Chem 2006;13:591-602.
200. Heales SJ, Lam AA, Duncan AJ, Land JM. Neurodegeneration or neuroprotection: the pivotal role of astrocytes. Neurochem Res 2004;29:513-9.
201. Durrenberger PF, Filiou MD, Moran LB, Michael GJ, Novoselov S, Cheetham ME et al. DnaJB6 is present in the core of Lewy bodies and is highly up-regulated in parkinsonian astrocytcs. J Neurosci Res 2009;87:238-45.
202. Gentile V Cooper AJ. Transglutaminases - possible drug targets in human diseases. Curr Drug Targets CNS Neurol Disord 2004;3:99-104.
203. Folk JE, Finlayson JS. The epsilon-(gamma-glutamyl)lysine crosslink and the catalytic role of transglutaminases. Adv Protein Chem 1977;31:1-133.
204. Lorand L, Graham RM. Transglutaminases: crosslinking enzymes with plciotropic functions. Nat Rev Mol Cell Biol 2003;4:140-56.
205. Fesus L, Davies PJ, Piacentini M. Apoptosis: molecular mechanisms in programmed cell death. Eur J Cell Biol 1991;56:170-7.
206. Vermes I, Haanen C, Reutelingsperger C. Flowcytometry of apoptotic cell death. J Immunol Methods 2000;243:167-90.
207. Fesus L, Piacentini M. Transglutaminase 2: an enigmatic enzyme with diverse functions. Trends Biochem Sci 2002;27:534-9.
208. Vulokhina EB, Hulshof R, Haancn C, Vermes I. Tissue transglutaminase mRNA expression in apoptotic cell death. Apoptosis 2003;8:673-9.
209. Vermes I, Steur EN, Jirikowski GF, Haanen C. Elevated concentration of cerebrospinal fluid tissue transglutaminase in Parkinson's disease indicating apoptosis. Mov Disord 2004;19:1252-4.
210. Tanner CM. The role of environmental toxins in the etiology of Parkinsons disease. Trends Neurosci 1989;12:49-54.
211. Tanner CM, Chen B, Wang W, Peng M, Liu Z, Liang X et al. Environmental factors and Parkinson's disease: a case-control study in China. Neurology 1989;39:660-4.
212. Di Monte DA. The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins? Lancet Neurol 2003;2:531-8.
213. McCormack AL, Thiruchelvam M, Manning-Bog AB, Thiffault C, Langston JW, Cory-Slechta DA, et al. Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol Dis 2002;10:119-27.
214. Di Monte DA, Lavasani M, Manning-Bog AB. Environmental factors in Parkinson's disease. Neurotoxicology 2002;23:487-502.
215. Di Monte DA. The role of environmental agents in Parkinson's disease. Clin Neurosci Res 2001;1:419-26.
216. Uversky VN. Neurotoxicant-induced animal models of Parkinsons disease: understanding the role of rotenone, maneb and paraquat in neurodegeneration. Cell Tissue Res 2004;318:225-41.
217. Ragonese P, Salemi G. Morgante L, Aridon P, Epifanio A, Buffa D et al. A case-control study on cigarette, alcohol, and coffee consumption preceding Parkinson's disease. Neoroepidemiology 2003;22:297-304.
218. Ross GW, Petrovitch H. Current evidence for neuroprotective effects of nicotine and caffeine against Parkinson's disease. Drugs Aging 2001;18:797-806.
219. Ross GW, Abbott RD, Petrovitch H, Morens DM, Grandinetti A, Tung KH et al. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA 2000;283:2674-9.
220. Hirsch EC, Brandel JP, Galle P, Javoy-Agid F, Agid Y. Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis. J Neurochem 1991;56:446-51.
221. Yasui M, Kthim T, Ota K. Calcium, magnesium and aluminum concentrations in Parkinson's disease. Neurotoxicology 1992;13:593-600.
222. Good PF, Olanow CW, Perl DR Neuromelanin-contaming neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study. Brain Res 1992;593:343-6.
223. Gorell JM, Johnson CC, Rybicki BA, Peterson EL, Kortsha GX, Brown GG et al. Occupational exposure to manganese, copper, lead, iron, mercury and zinc and the risk of Parkinson's disease. Neurotoxicology 1999;20:239-47.
224. Gorell JM, Rybicki BA, Johnson CC, Peterson EL. Occupational metal exposures and the risk of Parkinson's disease. Neuroepidemiology 1999;18:303-8.
225. Altschuler E. Aluminum-containing antacids as a cause of idiopathic Parkinson's disease. Med Hypotheses 1999;53:22-3.
226. Seidler A, Hellenbrand W, Robra BP, Vieregge P, Nischan P, Joerg J et al. Possible environmental, occupational, and other etiologic factors for Parkinson's disease: a case-control study in Germany. Neurology 1996;46:1275-84.
227. Davis LE, Adair JC. Parkinsonism from methanol poisoning: benefit from treatment with anti-Parkinson drugs. Mov Disord 1999;14:520-2.
228. Hageman G, van der Hock J, van Hout M, van der Laan G, Steur EJ, de Bruin W et al. Parkinsonism, pyramidal signs, polyneuropathy, and cognitive decline after long-term occupational solvent exposure. J Neurol 1999;246:198-206.
229. Pezzoli G, Strada O, Silani V, Zecchinelli A, Perbellini L, Javoy-Agid F et al. Clinical and pathological features in hydrocarbon-induced parkinsonism. Ann Neurol 1996;40:922-5.
230. Uitti RJ, Snow BJ, Shinotoh H, Vingerhoen FJ, Hayward M, Hashimoto S et al. Parkinsonism induced by solvent abuse. Ann Neurol 1994;35:616-9.
231. Klawans HL, Stein RW, Tanner CM, Goetz CG. A pure parkinsonian syndrome following acute carbon monoxide intoxication. Arch Neurol 1982;39:302-4.
232. Langston JW, Ballard PA, Jr. Parkinson's disease in a chemist working with 1-mcthyl-4-phenyl-1,2,5,6- tetrahydropyridine. N Engl J Med 1983;309:310.
233. Gorell JM, Johnson CC, Rybicki BA, Peterson EL, Richardson RJ. The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living. Neurology 1998;50:1346-50.
234. Fall PA, Fredrikson M, Axelson 0, Granerus AK. Nutritional and occupational factors influencing the risk of Parkinsons disease: a case-control study in southeastern Sweden. Mov Disord 1999;14:28-37.
235. Semchuk KM Love EJ, Lee RG. Parkinson's disease: a test of the multifactorial etiologic hypothesis. Neurology 1993;43:1173-80.
236. Semchuk KM, Love EJ, Lee RG. Parkinson's disease and exposure to agricultural work and pesticide chemicals. Neurology 1992;42:1328-35.
237. Liou HH, Tsai MC, Chen J,JengJS, Chang YC, Chen SY et al. Environmental risk factors and Parkinson's disease: a ease-control stody in Taiwan. Neorology 1997;48:1583-8.
238. Vanaeore N, Nappo A, Gentile M, Brustolin A, Palange S, Liberati A et al. Evaluation of risk of Parkinson's disease in a cohort of licensed pesticide users. Neurol Sei 2002;23(Suppl 2):5119-20.
239. Hertaman C, Wiens M, Snow B, Kelly S, Calne D. A ease-control study of Parkinson's disease in a horticultural region of British Columbia. Mov Disord 1994;9:69-75.
240. Vila M, Vukosavie S, Jackson-Lewis V. Neystat M, Jakowec M, Przedborski S. Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP. J Neuroehem 2000;74:721-9.
241. Manning-Bog AB, MeCormack AL, Li J, Uversky VN, Pink AL, Di Monte DA. The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. J Biol Chem 2002;277:1641-44.
242. Sherer TH, Kim JH. Betarbet R, Greenamyre JT. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuelein aggregation. Exp Neurol 2003;179:9-16.
243. Uversky VN, Li J, Bower K, Fink AL. Synergistic effects of pesticides and metals on the fibrillation of alphasynuelein: implications for Parkinsons disease. Neurotoxicology 2002;23:527-36.
244. Uversky VN, Li J, Fink AL, Pesticides directly accelerate the rate of alpha-synuclein fibril formation: a possible factor in Parkinson's disease. PEBS Lett 2001;500: 105-8.
245. Zayed J, Ducic S. Campanella G, Panisset JC, Andre P. Masson H et al. Environmental factors in the etiology of Parkinson's disease. Can J Neurol Sci 1990:17:286-91.
246. Rybicki BA, Johnson CC, Uman J, Gorell JM, Parkinson's disease mortality and the industrial use of heavy metals in Michigan. Mov Disord 1993;8:87-92.
247. Riederer P Sofic E, Rausch WD, Schmidt B, Reynolds GP, Jellinger K et al. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. Neurochem l989;52:5l5-20.
248. Dexter DY, Carayon A, Javoy-Agid F, Agid V. Wells PR, Daniel SE et al. Alterations in the levels of iron. ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 1991;114:1953-75.
249. Paik SR Shin HJ, LeeJH, Chang CS. KimJ. Copper(II)-induced self-oligomerization of alpha-synuclein. Biochem J 1999;340:821-28.
250. Uversky VN. Li J, Fink AL. Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuelein. A possible molecular NK between Parkinson's disease and heavy metal exposure. J Biul Chem 2001;276:44284-96.
251. Munishkina LA, Phelan C. Uversky VN. Fink AL. Conformational behavior and aggregation of alphasynuclein in organic solvents: modeling the effects of membranes. Biochemist' 2003;42:2720-30.
252. Mqran LB, Mickey L, Michael GJ. Derkacs M. Christian LM, Kalaitzakis ME et al. Neuronal pentraxin II is highly upregulated in Parkinson's disease and a novel component of Lewy bodies. Acta Neuropathol 2008;115:471-8.